IP Library Patent Application 12927687
Patent Application
App. No. 12/927,687

CD38 as a prognostic indicator in chronic lymphocytic leukemia

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/927,687
Abstract

The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.

Claims (6)

1 - 14 . (canceled)

15 . A method for determining the prognosis of B cell chronic lymphocytic leukemia (“B-CLL”) in a subject with B-CLL, the method comprising

determining whether a blood sample from the subject comprises B-CLL cells having a mutated Ig V gene,

wherein the absence of a mutated Ig V gene indicates a poor prognosis versus an indolent disease course.

16 . The method of claim 15 , wherein whether the Ig V gene is mutated is assessed by comparing the DNA sequence of the Ig V gene of the B-CLL cells of the sample with a control germline DNA sequence of the Ig V gene, wherein a ≧2% difference between the DNA sequence of the Ig V gene of the B-CLL cells of the sample and the control germline DNA sequence of the Ig V gene is indicative of a mutated Ig V gene.

17 . The method of claim 15 , wherein whether the Ig V gene is mutated is assessed by comparing the DNA sequence of the Ig V H gene or Ig V L gene of the B-CLL cells of the sample with a control germline DNA sequence of the Ig V H gene or Ig V L gene, wherein a ≧2% difference between the DNA sequence of the Ig V H gene or Ig V L gene of the B-CLL cells of the sample and the control germline DNA sequence of the Ig V H gene or Ig V L gene, respectively, is indicative of a mutated Ig V gene.

Assignments (2)
CHANGE OF NAME Recorded Apr 17, 2018
From: NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE
To: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 045967/0856 →
CONFIRMATORY LICENSE Recorded Jun 6, 2011
From: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026391/0261 →